Oragenics Inc (OGEN)
0.46
-0.00 -0.86%
NYSE AM
Oct 17, 17:00
Real time
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -0.6536 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -13.65M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0% |
| Price and Valuation | |
| Market Cap | 21.22M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 12.47 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 1.185 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | -- |
| Free Cash Flow (Quarterly) | -3.499M |
| Return on Equity (TTM) | Upgrade |
View All OGEN News
News
-
WireHeadlineTime (ET)
-
Yahoo10/02 08:15
-
Business Wire09/30 08:00
-
Business Wire09/25 08:00
-
Business Wire09/23 08:00
-
Yahoo09/10 10:41
-
Business Wire09/06 17:29
-
Business Wire08/20 08:00
-
MT Newswires06/25 10:10
-
Business Wire06/25 08:30
-
MT Newswires06/17 08:59
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.oragenics.com
- Investor Relations URL: http://www.oragenics.com/?q=investors
- HQ State/Province: Florida
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: N/A
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics involves in developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for out licensing or partnering.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 0.46 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- OGEN Tweets Stocktwits
Advertisement
